Archive: February 18 2021

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Onclive13

Dr. Solomon on the Effects of Liso-Cel in Prior Anti-CD19 Therapy–Treated B-NHL

Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.

Visit website
Immunotherapy Web Featured Images 111

Can BiTE Molecules Make Off-the-Shelf Immuno-Oncology a Reality?

  Feb 18 2021 Tagged mAbs, BiTE, MM, NHL, LBCL

In hematologic malignancies, a new class of molecules is emerging that may ultimately offer clinical benefits comparable to those chimeric antigen receptor T-cell therapies while reducing some of the negatives associated with them.

Visit website
Targeted10

Key Takeaways from the First-in-Human Study of Odronextamab in B-cell NHL

  Feb 18 2021 Tagged mAbs, BiTE, NHL

Rajat Bannerji, MD, PhD, discussed key takeaways from the phase 1 study of the novel CD20xCD3 bispecific antibody, odronextamab in patients with highly refractory B-cell non-Hodgkin lymphoma.

Visit website
Immunotherapy Web Featured Images 110

CAR-T Meeting 2021 | CAR-T vs. BiTEs in B-cell malignancies

  Feb 18 2021 Tagged CAR-T, BiTE

Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, compares CAR T-cells to bispecific T-cell engagers (BiTEs). Firstly, Prof. Subklewe highlights that there are no randomized trials in any disease comparing CAR T-cells to BiTEs.

Visit website